NCT07213960View on ClinicalTrials.gov

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

December 31, 2029

Conditions
FSGS
Interventions
DRUG

APL2

Complement (C3) Inhibitor

OTHER

Placebo

Sterile solution of equal volume to active arm

Trial Locations (2)

10032

Investigator Site 2, New York

60643

Investigator Site 1, Chicago

Sponsors
All Listed Sponsors
lead

Apellis Pharmaceuticals, Inc.

INDUSTRY

NCT07213960 - A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis | Biotech Hunter | Biotech Hunter